- Klaus Stohr, Global Head of Influenza Franchises at Novartis to Give Plenary Keynote at the Infectious Diseases World Summit 2013
Product News: Klaus Stohr, Global Head of Influenza Franchises at Novartis to Give Plenary Keynote at the Infectious Diseases World Summit 2013Klaus Stohr, Vice President and Global Head of Influenza Franchises at Novartis, will give a keynote presentation titled "Global Trends in Pandemic Preparedness: Changes After the Last Pandemic?" at GTC's Infectious Diseases World Summit 2013 on July 8-10, 2013 in Boston, MA. Dr. Stohr's presentation will discuss efforts to accelerate pandemic vaccine investment and their need to acknowledge that it is mainly driven from two sources: political commitment to preparedness/public health or opportunities available from seasonal influenza vaccine use/manufacturing.
The Infectious Diseases World Summit 2013 will bring together experts from industry, academia, and the public sector to discuss cutting edge research and new technologies used in the pharmaceutical and biotech fields. It will also give global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, explore potential collaborations, and learn about relevant infectious diseases issues and deals that will affect the industry.
Featured speakers include Kathrin Jansen, Senior Vice President of Vaccine Research East & Early Development at Pfizer, Nathalie Garcon, Vice President and Head of the Global Adjuvant Center for Vaccines at GSK, Derek O'Hagan, Vice President and Global Head of Vaccine Delivery and Formulation Research at Novartis V&D, Jaap Goudsmit, Founder and Chief Scientist at the Crucell Vaccine Institute and Janssen Center of Excellence for Immunoprophylaxis, Robin Robinson, Director of Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health & Human Services
Registration to the Infectious Diseases World Summit 2013 gives access to the 3 concurrent tracks:
. 11th Vaccines Research & Development: All Things Considered
. 2nd Influenza Research and Development
. 10th Anti-Infectives Partnering and Deal-making